Recent Updates
Recently added Catalysts
PCRX Positive Sentiment

Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference

Key Takeaway: Pacira BioSciences, Inc. will take part in the Barclays Global Healthcare Conference on March 15, 2023, in Miami. The company aims to highlight its commitment to offering non-opioid treatment alternatives and its innovative interventions for various conditions. Key products include EXPAREL®, ZILRETTA®, and iovera®—each addressing specific pain management requirements. Live audio of the event will be accessible on the company's investor website, with a replay available afterward.
Price reaction · baseline $40.41 (2023-03-07 close) · hit after-hours · clean, no other PCRX news in the window
day 0 close · peak
-2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira BioSciences is participating in a prominent healthcare conference.
  • The company is committed to providing non-opioid treatment options.
  • Pacira has several commercial-stage non-opioid products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.7%
average across 5 past catalysts
Lead asset
FX006
Phase 2 · Osteoarthritis of the Shoulder

Full Press Release Details

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Frequently Asked Questions

When is Pacira's fireside chat at the Barclays Conference?

Pacira's fireside chat is scheduled for March 15, 2023, at 9:00 AM ET.

How can I access the live audio of the event?

Live audio can be accessed on Pacira's website under the 'Events' page.

What is Pacira's goal regarding opioid use?

Pacira aims to redefine opioids as rescue therapy by providing non-opioid options.

What non-opioid treatments does Pacira offer?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® for pain management.

Where can I learn more about Pacira BioSciences?

More information is available at Pacira's official website, www.pacira.com.

Last updated: Mar 8, 2023